Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tuspetinib - Aptose Biosciences

Next Previous
Drug Profile

Tuspetinib - Aptose Biosciences

Alternative Names: C0WUS7XXE9; HM-43239; TUS

Latest Information Update: 17 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hanmi Pharmaceutical
  • Developer Aptose Biosciences
  • Class Alkaloids; Antineoplastics; Benzene derivatives; Camptothecins; Chlorinated hydrocarbons; Cyclopropanes; Indoles; Piperazines; Pyrimidines; Small molecules; Toluenes
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Janus kinase 1 inhibitors; Janus kinase 2 inhibitors; MAP kinase kinase kinase 7 inhibitors; Proto-oncogene protein c-kit inhibitors; Syk kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia

Most Recent Events

  • 12 Jun 2025 Efficacy and adverse events data from a phase I/II TUSCANY trial in Acute myeloid leukaemia released by Aptose Biosciences
  • 08 May 2025 Updated efficacy and safety data from a phase I/II trial in Acute myeloid leukaemia released by Aptose Biosciences
  • 08 May 2025 Aptose Biosciences plans a pivotal phase II/III trial for Acute myeloid leukemia

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top